<VariationArchive RecordType="classified" VariationID="1698512" VariationName="NC_000023.10:g.(?_119560002)_(119603205_?)del" VariationType="Deletion" Accession="VCV001698512" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-08-12" DateCreated="2022-08-03" MostRecentSubmission="2022-08-03">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1690889" VariationID="1698512">
      <GeneList>
        <Gene Symbol="LAMP2" FullName="lysosomal associated membrane protein 2" GeneID="3920" HGNC_ID="HGNC:6501" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>Xq24</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="120426148" stop="120469349" display_start="120426148" display_stop="120469349" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="119560002" stop="119603203" display_start="119560002" display_stop="119603203" Strand="-" />
          </Location>
          <OMIM>309060</OMIM>
          <Haploinsufficiency last_evaluated="2021-02-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LAMP2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-02-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LAMP2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000023.10:g.(?_119560002)_(119603205_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq24</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" innerStart="119560002" innerStop="119603205" display_start="119560002" display_stop="119603205" variantLength="43204" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.(?_119560002)_(119603205_?)del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.(?_119560002)_(119603205_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000023.10:g.(?_119560002)_(119603205_?)del AND Danon disease" Accession="RCV002271789" Version="1">
        <ClassifiedConditionList TraitSetID="2823">
          <ClassifiedCondition DB="MedGen" ID="C0878677">Danon disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-06-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-06-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-08-03" MostRecentSubmission="2022-08-03">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">31729179</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2823" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1699" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PSEUDOGLYCOGENOSIS II</ElementValue>
                <XRef Type="MIM" ID="300257" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GSD IIb</ElementValue>
                <XRef Type="MIM" ID="300257" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">LYSOSOMAL GLYCOGEN STORAGE DISEASE WITHOUT ACID MALTASE DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="300257" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Danon disease</ElementValue>
                <XRef ID="Danon+Disease/2114" DB="Genetic Alliance" />
                <XRef ID="MONDO:0010281" DB="MONDO" />
                <XRef ID="419097006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Vacuolar cardiomyopathy and myopathy X-linked</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Antopol disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pseudoglycogenosis 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen storage disease limited to the heart</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen storage cardiomyopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen storage disease type 2b (formerly)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lysosomal glycogen storage disease without acid maltase deficiency (formerly)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GSD2B (formerly)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen Storage Disease Type IIb</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GSD2B</ElementValue>
                <XRef Type="MIM" ID="300257" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Danon disease is a multisystem condition with predominant involvement of the heart, skeletal muscles, and retina, with overlying cognitive dysfunction. Males are typically more severely affected than females. Males usually present with childhood onset concentric hypertrophic cardiomyopathy that is progressive and often requires heart transplantation. Rarely, hypertrophic cardiomyopathy can evolve to resemble dilated cardiomyopathy. Most affected males also have cardiac conduction abnormalities. Skeletal muscle weakness may lead to delayed acquisition of motor milestones. Learning disability and intellectual disability, most often in the mild range, are common. Additionally, affected males can develop retinopathy with subsequent visual impairment. The clinical features in females are broader and more variable. Females are more likely to have dilated cardiomyopathy, with a smaller proportion requiring heart transplantation compared to affected males. Cardiac conduction abnormalities, skeletal muscle weakness, mild cognitive impairment, and pigmentary retinopathy are variably seen in affected females.</Attribute>
                <XRef ID="NBK554742" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9730" />
                <XRef ID="9730" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">32134616</ID>
                <ID Source="BookShelf">NBK554742</ID>
              </Citation>
              <XRef ID="34587" DB="Orphanet" />
              <XRef ID="C0878677" DB="MedGen" />
              <XRef ID="MONDO:0010281" DB="MONDO" />
              <XRef Type="MIM" ID="300257" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5001030" SubmissionDate="2022-07-29" DateLastUpdated="2022-08-03" DateCreated="2022-08-03">
        <ClinVarSubmissionID localKey="NC_000023.10:g.(?_119560002)_(119603205_?)del|MedGen:C0878677" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002555744" DateUpdated="2022-08-03" DateCreated="2022-08-03" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">31729179</ID>
          </Citation>
          <Comment>Variant summary: The variant identified by MLPA or other technology involves the deletion of the entire coding region of the LAMP2 gene. A presumed nomenclature of c.(?_-181)_(*5176_?)del has been designated for the purposes of this classification. The variant was absent in 16107 control chromosomes (gnomAD, Structural Variants dataset). One female Danon Disease patient with a de novo deletion variant involving partial loss of CUL4B and complete loss of LAMP2, ATP1B4, TMEM255A and ZBTB33 genes, has been reported in the literature (Majer_2020). One ClinVar submitter has assessed the variant since 2014: the variant was classified as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="LAMP2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.(?_119560002)_(119603205_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0878677" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11876943</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5001030" TraitType="Disease" MappingType="XRef" MappingValue="C0878677" MappingRef="MedGen">
        <MedGen CUI="C0878677" Name="Danon disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

